By Sabela Ojea

 

Abbott Laboratories said it has received positive results from its chronic limb-threatening ischemia trial and it expects to submit the drug for review by the U.S. Food and Drug Administration.

The medical devices and health care company on Wednesday said the trial met both primary safety and effectiveness endpoints and showed that its Esprit BTK drug reduces disease progression.

Chronic limb-threatening ischemia is a form peripheral arterial disease, which causes an accumulation of plaque in the arteries in legs or arms.

About 22 million people worldwide have been affected by chronic limb-threatening ischemia.

 

Write to Sabela Ojea at sabela.ojea@wsj.com

 

(END) Dow Jones Newswires

October 25, 2023 15:02 ET (19:02 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Jan 2024 à Fév 2024 Plus de graphiques de la Bourse Abbott Laboratories
Abbott Laboratories (NYSE:ABT)
Graphique Historique de l'Action
De Fév 2023 à Fév 2024 Plus de graphiques de la Bourse Abbott Laboratories